Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?
2006/01/13 by Michael J Duffy, Michael J. Duffy · 27 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Glycosylation and Glycoproteins Research #HER2/EGFR in Cancer Research #Breast Cancer Treatment Studies
paper · doi:10.1373/clinchem.2005.059832
Abstract
BACKGROUND: Although multiple serum-based tumor markers have been described for breast cancer, such as CA 15-3, BR 27.29 (CA27.29), carcinoembryonic antigen (CEA), tissue polypeptide antigen, tissue polypeptide specific antigen, and HER-2 (the extracellular domain), the most widely used are CA 15-3 and CEA. METHODS: The literature relevant to serum tumor markers in breast cancer was reviewed. Particular attention was given to systematic reviews, prospective randomized trials, and guidelines issued by expert panels. RESULTS: Because of a lack of sensitivity for early disease and lack of specificity, none of the available markers is of value for the detection of early breast cancer. High preoperative concentrations of CA 15-3 are, however, associated with adverse patient outcome. Although serial determinations of tumor markers after primary treatment for breast cancer can preclinically detect recurrent/metastatic disease with lead times of approximately 2-9 months, the clinical value of this lead time remains to be determined. Serum markers, however, are the only validated approach for monitoring treatment in patients with advanced disease that cannot be evaluated by use of conventional criteria. CONCLUSIONS: CA 15-3 is one of the first circulating prognostic factors for breast cancer. Preoperative concentrations thus might be combined with existing prognostic factors for predicting outcome in patients with newly diagnosed breast cancer. At present, the most important clinical application of CA 15-3 is in monitoring therapy in patients with advanced breast cancer that is not assessable by existing clinical or radiologic procedures.
Cited by
- National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
- Bacterial diversity in the caecum of the rabbit.
- A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression
- CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. [europepmc]
- Toward unraveling the complexity of simple epithelial keratins in human disease. [europepmc]
- Early detection of recurrent breast cancer using metabolite profiling. [europepmc]
- Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. [europepmc]
- The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? [europepmc]
- Bony metastases: assessing response to therapy with whole-body diffusion MRI. [europepmc]
- Heat shock proteins as danger signals for cancer detection. [europepmc]
- Identifying cancer biomarkers by mass spectrometry-based glycomics. [europepmc]
- miRNA profiling of cancer. [europepmc]
- Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis? [europepmc]
- Early detection of breast cancer using total biochemical analysis of peripheral blood components: a preliminary study. [europepmc]
- Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer. [europepmc]
- Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics. [europepmc]
- Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients. [europepmc]
- Healthy human serum N-glycan profiling reveals the influence of ethnic variation on the identified cancer-relevant glycan biomarkers. [europepmc]
- Circulating miRNAs in Untreated Breast Cancer: An Exploratory Multimodality Morpho-Functional Study. [europepmc]
- Fourier Transform Infrared Spectroscopy as a Cancer Screening and Diagnostic Tool: A Review and Prospects. [europepmc]
- Application of metabolomics in the diagnosis of breast cancer: a systematic review. [europepmc]
- Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance. [europepmc]
- Non-Invasive Biomarkers for Early Detection of Breast Cancer. [europepmc]
- Breast Cancer; Discovery of Novel Diagnostic Biomarkers, Drug Resistance, and Therapeutic Implications. [europepmc]
- Whole-genome bisulfite sequencing analysis of circulating tumour DNA for the detection and molecular classification of cancer. [europepmc]
- A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancer. [europepmc]
- Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice. [europepmc]
- Tumor biomarkers for diagnosis, prognosis and targeted therapy. [europepmc]
Related